Cytek Biosciences, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 7 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−0.48%
vs ±72.4% implied · ×0.01
shaded = implied · ▲▼ = realized
Cytek Biosciences has 5 disclosed suppliers and 0 disclosed customers in SEC filings.
SentenceAs part of the settlement, BD granted us a non-exclusive, irrevocable, perpetual, worldwide, and non-transferrable license to certain BD patents and covenanted that it would not enforce, or permit or encourage the enforcement of BD patents against us or our affiliates in connection with the development, manufacture, use, importation, offer for sale or sale of our then-current instruments.
SentenceOn September 1, 2020, we entered into a Supply and License Agreement with Biotium, Inc. ("Biotium") pursuant to which Biotium agreed to supply, and we obtained a worldwide, non-exclusive license to market and resell to our customers and distributors, certain Biotium products to conjugate proteins and/or antibodies and to use such conjugates as a component in our cFluor reagent products, for research and analyte specific reagents (as defined by 21 CFR 864.4020) use only (the "Field of Use") (the "Biotium Agreement").
CTKB 10-Kaccession 0001628280-26-012352
SentencePursuant to the Coherent Agreement, Coherent has agreed to sell and supply to us, Cytek Wuxi, and Cytek Singapore, on a non-exclusive basis, laser products manufactured by Coherent.
CTKB 10-Kaccession 0001628280-26-012352
SentenceNet cash used in investing activities during the year ended December 31, 2024 was $83.0 million driven by purchases of marketable securities of $274.1 million, purchases of property and equipment of $3.5 million, the purchase of the Cytometric Engineering Ltd. (d.b.a. FlowCEL) business of $0.5 million, and purchase of intangible assets of $0.2 million, partially offset by proceeds from maturities of marketable securities of $195 million, and proceeds from sales of property and equipment of $0.3 million.
CTKB 10-Kaccession 0001628280-26-012352
SentenceFor example, in February 2023, we entered into an asset purchase agreement with Luminex Corporation ("Luminex") and acquired certain assets related to the flow cytometry and imaging business unit of Luminex (the "FCI Acquisition").
CTKB 10-Kaccession 0001628280-26-012352
Cytek Biosciences, Inc.
6.13
−0.17 · −2.78%
post 6.13 0.00%
—
—
Linked news
Expected move
No implied move.